Eli Lilly and Roche ask CMS not to be lumped in with Aduhelm’s restrictive judgment
With CMS closing its public comment period for its draft decision to limit coverage of Biogen’s Aduhelm last week, two Big Pharma companies developing similar Alzheimer’s drugs got in their comments just before Thursday’s deadline.
Eli Lilly and Roche both posted lengthy letters to the CMS site aiming to convince CMS to reverse its ruling restricting Aduhelm coverage to patients in clinical studies. The pair has a lot on the line as their own anti-amyloid antibodies make their way through the FDA review period.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.